Gubra A/S Logo

Gubra A/S

Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.

GUBRA | CO

Overview

Corporate Details

ISIN(s):
DK0062266474
LEI:
254900T17RRFZONO6W53
Country:
Denmark
Address:
Hørsholm Kongevej 11 B, 2970 Hørsholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Gubra is a biotechnology company and preclinical Contract Research Organization (CRO) founded in 2008. The company operates a dual business model, providing specialized preclinical research services while simultaneously developing its own pipeline of peptide-based therapeutics. Gubra's core expertise lies in metabolic diseases (such as obesity, diabetes, and MASH) and fibrotic diseases. Its CRO services support pharmaceutical and biotech clients with advanced studies, including in vivo pharmacology and peptide chemistry. The drug discovery division focuses on advancing a proprietary portfolio of novel drug candidates, with research and development efforts also extending into inflammatory, CNS, respiratory, and women's health conditions. This integrated approach combines stable service revenue with the long-term potential of therapeutic innovation.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Gubra A/S and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Gubra A/S filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Gubra A/S via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Adocia Logo
Developing novel drug formulations for metabolic diseases like diabetes and obesity for out-licensing.
France ADOC
Aladdin Healthcare Technologies SE Logo
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany NMI
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs for cancer, with a lead candidate for pancreatic cancer.
Sweden ATORX
Alten Logo
Global engineering and IT consulting for digital transformation in industry and telecom sectors.
France ATE
AlzeCure Pharma Logo
Clinical-stage pharma developing drugs for CNS diseases like Alzheimer's and pain.
Sweden ALZCUR
Alzinova AB Logo
Develops immunotherapies and vaccines to treat and prevent Alzheimer's disease.
Sweden ALZ
Amoéba Logo
Develops amoeba-based natural fungicides for agriculture and active ingredients for cosmetics.
France ALMIB
Annexin Pharmaceuticals AB Logo
Clinical-stage biotech developing Annexin A5 protein therapies for ophthalmology and oncology.
Sweden ANNX
Aptahem AB Logo
Develops RNA-based aptamer drugs for acute, life-threatening conditions like sepsis.
Sweden APTA
APTAMER GROUP PLC Logo
Develops custom aptamer-based binders as antibody alternatives for life science applications.
United Kingdom APTA

Talk to a Data Expert

Have a question? We'll get back to you promptly.